T cell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity

Journal of Immunology

Volumn 178, Issue 6, 2007, Pages 3962-3972

  Rus, Violeta ^a,b   Nguyen, Vinh ^a,b   Puliaev, Roman ^c   Puliaeva, Irina A ^c   Zernetkina, Valentina ^a,b   Luzina, Irina ^a,b   Papadimitriou, John C ^b   Via, Charles S ^c  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; GENE EXPRESSION; GLOMERULONEPHRITIS; KNOCKOUT MOUSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 33947278280     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.6.3962     Document Type: Article

References (63)

1. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17: 221-253.
2. Ware, C. F., S. VanArsdale, and T. L. VanArsdale. 1996. Apoptosis mediated by the TNF-related cytokine and receptor families. J. Cell. Biochem. 60: 47-55.
3. Jeremias, I., I. Herr, T. Boehler, and K. M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28: 143-152.
4. Martinez-Lorenzo, M. J., M. A. Alava, S. Gamen, K. J. Kim, A. Chuntharapai, A. Pineiro, J. Naval, and A. Anel. 1998. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28: 2714-2725.
5. + T cell killing of antigen-presenting macrophages. J. Immunol. 164: 2897-2904.
6. Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690.
7. Matsuyama, W., M. Yamamoto, I. Higashimoto, K. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, and K. Arimura. 2004. TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 104: 184-191.
8. Ursini-Siegel, J., W. Zhang, A. Altmeyer, E. N. Hatada, R. K. Do, H. Yagita, and S. Chen-Kiang. 2002. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J. Immunol. 169: 5505-5513.
9. + T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/ DR5-mediated apoptosis. Blood 106: 3524-3531.
10. + T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. USA 102: 13974-13979.
11. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T, D. Smith, C. Rauch, C. A. Smith, et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
12. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7: 821-830.
13. Secchiero, P., A. Gonelli, E. Carnevale, D. Milani, A. Pandolfi, D. Zella, and G. Zauli. 2003. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107: 2250-2256.
14. Morel, J., R. Audo, M. Hahne, and B. Combe. 2005. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280: 15709-15718.
15. Yurovsky, V. V. 2003. Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 28: 225-231.
16. Li, J. H., N. C. Kirkiles-Smith, J. M. McNiff, and J. S. Pober. 2003. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 171: 1526-1533.
17. Lunemann, J. D., S. Waiczies, S. Ehrlich, U. Wendling, B. Seeger, T. Kamradt, and F. Zipp. 2002. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168: 4881-4888.
18. Chou, A. H., H. F. Tsai, L. L. Lin, S. L. Hsieh, P. I. Hsu, and P. N. Hsu. 2001. Enhanced proliferation and increased IFN-γ production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J. Immunol. 167: 1347-1352.
19. Tsai, H. F., J. J. Lai, A. H. Chou, T. F. Wang, C. S. Wu, and P. N. Hsu. 2004. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum. 50: 629-639.
20. Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, and B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191: 1095-1104.
21. Lamhamedi-Cherradi, S. E., S. Zheng, R. M. Tisch, and Y. H. Chen. 2003. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52: 2274-2278.
22. -/- mice. Nat. Immunol. 4: 255-260.
23. Mi, Q. S., D. Ly, S. E. Lamhamedi-Cherradi, K. V. Salojin, L. Zhou, M. Grattan, C. Meagher, P. Zucker, Y. H. Chen, J. Nagle, et al. 2003. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52: S1967-1975.
24. Billiard, B., A. Wilmen, C. Seidel, T. S. Liu, R. Goke, and Y. Chen. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166: 1314-1319.
25. Schmaltz, C., O. Alpdogan, B. J. Kappel, S. J. Muriglan, J. A. Rotolo, J. Ongchin, L. M. Willis, A. S. Greenberg, J. M. Eng, J. M. Crawford, et al. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8: 1433-1437.
26. Diehl, G. E., H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley, and A. Winoto. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877-889.
27. Rus, V., S. P. Atamas, V. Shustova, I. G. Luzina, F. Selaru, L. S. Magder, and C. S. Via. 2002. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin. Immunol. 102: 283-290.
28. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
29. Kaplan, M. J., E. E. Lewis, E. A. Shelden, E. Somers, R. Pavlic, W. J. McCune, and B. C. Richardson. 2002. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J. Immunol. 169: 6020-6029.
30. Rus, V., V. Zernetkina, R. Puliaev, C. Cudrici, S. Mathai, and C. S. Via. 2005. Increased expression and production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients is a feature of active disease. Clin. Immunol. 117: 48-56.
31. Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168: 1356-1361.
32. + T cells. J. Immunol. 155: 2396-2406.
33. Via, C. S., V. Rus, M. K. Gately, and F. D. Finkelman. 1994. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J. Immunol. 153: 4040-4047.
34. Thompson, B. S., and T. C. Mitchell. 2004. Measurement of daughter cell accumulation during lymphocyte proliferation in vivo. J. Immunol. Methods 295: 79-87.
35. Finkelman, F. D., and S. C. Morris. 1999. Development of an assay to measure in vivo cytokine production in the mouse. Int. Immunol. 11: 1811-1818.
36. Puliaev, R., P. Nguyen, F. D. Finkelman, and C. S. Via. 2004. Differential requirement for IFN-γ in CTL maturation in acute murine graft-versus-host disease. J. Immunol. 173: 910-919.
37. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
38. + T cells. J. Immunol. 171: 17-21.
39. Via, C. S., S. O. Sharrow, and G. M. Shearer. 1987. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J. Immunol. 139: 1840-1849.
40. T method. Methods 25: 402-408.
41. Luzina, I. G., R. H. Knitzer, S. P. Atamas, W. C. Gause, J. C. Papadimitriou, M. B. Sztein, C. E. Storrer, and B. S. Handwerger. 1999. Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells. Arthritis Rheum. 42: 561-568.
42. Gleichmann, E., S. T. Pals, A. G. Relink, T. Radaszkiewicz, and H. Gleichmann. 1984. Graft-versus-host reactions: clues to the etiology of a spectrum of immunological diseases. Immunol. Today 5: 324-328.
43. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189: 1451-1460.
44. Mariani, S. M., and P. H. Krammer. 1998. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28: 1492-1148.
45. Shustov, A., I. Luzina, P. Nguyen, J. C. Papadimitriou, B. Handwerger, K. B. Elkon, and C. S. Via. 2000. Role of perform in controlling B-cell hyper-activity and humoral autoimmunity. J. Clin. Invest. 106: R39-R47.
46. + T cell activation and IFN-γ production. J. Immunol. 161: 2848-2855.
47. Wu, G. S., T. F. Burns, Y. Zhan, E. S. Alnemri, and W. S. El-Deiry. 1999. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59: 2770-2775.
48. Kumar-Sinha, C., S. Varambally, A. Sreekumar, and A. M. Chinnaiyan. 2002. Molecular cross-talk between the TRAIL and interferon signaling pathways. J. Biol. Chem. 277: 575-585.
49. Von Wussow, P., D. Jakschies, H. Hochkeppel, M. Horisberger, K. Hartung, and H. Deicher. 1989. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 32: 914-918.
50. Shimizu, N., and Y. Sokawa. 1979. 2′,5′-Oligoadenylate synthetase activity in lymphocytes from normal mouse. J. Biol. Chem. 254: 12034-12037.
51. Legge, K. L., A. L. Katewa, E. Brincks, and T. S. Griffith. 2006. TRAIL deficiency increases the severity of influenza virus infections. J. Immunol. 176S: S119.
52. Cretney, E., A. Shanker, H. Yagita, M. J. Smyth, and T. J. Sayers. 2006. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 84: 87-98.
53. + T cell-mediated cytotoxicity. J. Immunol. 162: 2639-2647.
54. Sedger, L. M., D. M. Shows, R. A. Blanton, J. J. Peschon, R. G. Goodwin, D. Cosman, and S. R. Wiley. 1999. IFN-α mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163: 920-926.
55. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
56. Sato, K., S. Hida, H. Takayanagi, T. Yokochi, N. Kayagaki, K. Takeda, H. Yagita, K. Okumura, N. Tanaka, T. Taniguchi, and K. Ogasawara. 2001. Antiviral response by natural killer cells through TRAIL gene induction by IFN-αβ. Eur. J. Immunol. 31: 3138-3146.
57. + T cell blasts to regulation by APO2L/TRAIL. Eur. J. Immunol. 35: 1812-1821.
58. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88-93.
59. + T cells. Nat. Immunol. 7: 475-481.
60. Grader-Beck, T., L. Casciola-Rosen, T. J. Lang, R. Puliaev, A. Rosen, and C. S. Via. 2007. Apoptotic splenocytes drive the autoimmune response to poly-(ADP-ribose) polymerase 1 in a murine model of lupus. J. Immunol. 178:95-102.
61. Kayagaki, N., N. Yamaguchi, M. Abe, S. Hirose, T. Shirai, K. Okumura, and H. Yagita. 2002. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell. Immunol. 219: 82-91.
62. Tsokos, G. C., and J. E. Balow. 1983. Phenotypes of T lymphocytes in systemic lupus erythematosus: decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin A-induced suppressor cells. Clin. Immunol. Immunopathol. 26: 267-276.
63. Stohl, W. 1992. Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 63: 163-172.